甲磺酸阿帕替尼治疗晚期原发性肝癌的近期疗效观察

Therapeutic effect of apatinib on patients with advanced primary hepatic carcinoma

目的探讨阿帕替尼治疗晚期原发性肝癌的近期疗效与安全性。方法收集2015年6月至2017年12月于我院接受口服阿帕替尼500mg·d^(-1)治疗的20例晚期原发性肝癌患者的临床资料,回顾性分析经过2个疗程(28d/疗程)后患者的治疗效果,并对不良反应进行分析。结果可评估的18例患者中,部分缓解2例(11.1%),疾病稳定7例(38.9%),疾病进展9例(50.0%)。疾病控制率为50.0%,客观缓解率为11.1%。常见相关不良反应为疲乏(45%)、高血压(30%)、手足综合征(20%)等,主要为Ⅰ级或Ⅱ级,患者基本可以耐受。结论阿帕替尼治疗晚期原发性肝癌的近期疗效值得肯定,不良反应多可耐受。

Objective To evaluate the efficacy and safety of apatinib in patients with advanced primary hepatic carcinoma.Methods Twenty patients with advanced primary hepatic carcinoma in the Second Affiliated Hospital of Hainan Medical College between June 2015 and December 2017 were enrolled for evaluation.All patients were treated with 500 mg apatinib orally once a day.The efficacy and adverse reactions were observed and analyzed after two courses(28 days per course).Results A total of 18 patients finally completed at least two courses of treatment,and their clinical efficacy was evaluated.Of them,2 patients(11.1%)had partial response(PR),7 patients(38.9%)stable disease(SD),and 9 patients(50.0%)progressive disease(PD).The disease control rate(DCR)was 50.0%,and objective response rate(ORR)was 11.1%.The most common apatinib-related adverse reactions were fatigue(45%),hypertension(30%),hand-foot skin reaction(HFSR)(20%)and so on.Most were gradeⅠ-Ⅱadverse reactions and could be tolerated.Conclusion Apatinib is a safe and effective therapy in advanced primary hepatic carcinoma patients,and its adverse reactions can be tolerated.